Wearable glucose monitors help people with type 2 diabetes who do not use insulin, a major trial has found.

Until now, the devices have been recommended only for patients receiving insulin.

The six-month CONNECT trial enrolled 283 adults and was published in The New England Journal of Medicine.

Dexcom G7 users saw average A1C fall from 8.8% to 7.2%, versus 8.7% to 8.0% with routine care.

Monitor users spent about five more hours a day within the target glucose range.

The benefit held regardless of age, sex, race, body weight, income and use of glucose-lowering drugs.

By the study’s end, 97% of participants were still using the monitors, most of them daily.

The trial was sponsored by Dexcom, and patchy insurance coverage remains the biggest barrier to wider use.

Read the full article for more details on glucose monitors for type 2 diabetes.